Animal Model Market Size
Estimated to be valued at USD 19.4 billion in 2022, animal model market size is expected to rise at notable rate of 6.9% over the study period. Rising adoption of animal models for biomedical research, increasing expenditure and high investments in dug development and discover, increasing attention on precision medicine, and broad uses of animal models in the healthcare sector help to explain the high rate of market growth.
To get key market trends
With a 2.2% increase from 2019 to 2020, the estimated 797,546 laboratory animals used in biomedical research in 2021 according to U.S. government figures These figures add even more to the total number of animal models used for study by excluding the counts of mice, rats, and fish models.
A non-human, living, genetically altered animal utilized for scientific study of human diseases might be considered as an animal model. Furthermore, these animal models help to clarify the human disease process so as to avoid damaging a real human.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Animal Model Market Size in 2022 | USD 19.4 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 6.9% |
| 2032 Value Projection | USD 38.4 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 704 |
| Tables, Charts & Figures | 1,006 |
| Segments covered | Animal Type, Technology, Application, Use, End-use, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
What are the growth opportunities in this market?
COVID-19 Impact
The exceptional public health issue of COVID-19 has improved the market for animal models. The growing frequency of COVID-19 cases also mostly influenced the healthcare industry. Nonetheless, despite the epidemic, large expenditures in COVID-19-related research projects and rising support for R&D activities to generate new treatments have encouraged the use of animal models.
To concentrate on the epidemic, several pharmaceutical, biotechnology, and clinical research businesses changed their R&D budgets to support more clinical trials. Many animal models have been investigated and used in order to investigate COVID-19 infection. Particularly SARS-CoV-2 strain adapted mice following intentional passaging of virus in lung tissues, mice were extensively used in studies on infectious diseases. Such described element helped to explain the observed favorable effect during the COVID-19 epidemic.
Animal Model Market Trends
The market development is expected to be driven by the growing volume of pharmaceutical research and development projects. Among the main value drivers of research-based pharmaceutical and biotechnology companies are the need for new pharmaceuticals to help fulfill the unmet medical needs. The pharmaceutical industry creates various fresh medications with great clinical value. Among the main factors influencing the volume of pharmaceutical research and development activities are the explosive increase of investments by both public and private sectors.
For example, the Congressional Budget Office estimates that the pharmaceutical industry would have USD 83 billion in R&D expenditure in 2019. These expenses involve a wide range of activities, including research and testing for safety-parameters or regulatory needs as well as for new drugs.
Animal Model Market Restraint
Worldwide regulation of animal experimentation is mostly aimed at safeguarding animals and guaranteeing ethical treatment of them. Every nation has particular rules known as regulatory guidelines that researchers must abide by. Researchers must show that they have a valid cause for using animals in their studies and that the advantages exceed any negative effects on the animals before they can be used in such regard. They also have to prove that there are no other approaches to examine the identical issue devoid of animal use. Once accepted, a plan of action is examined by an IACUC (institutional animal care and use committee). This committee ensures that the study is set up so as to minimize animal suffering and treat them compassionately. Although these laws help to ensure that animals used in study are treated properly, they can also complicate researchers' job. New medical treatments and cures may so slow down their growth.
Animal Model Market Analysis
The animal model market is divided by typemice, rats, fish, birds, cattle's, pigs, amphibians, guinea pigs, dogs, cats, rabbits, monkey's, sheep, hamsters, and other animal kinds. With around 49.2% business share, the mouse segment controlled most of the market in 2022. Among the most often used animal models in research on human health and diseases is the mouse model. Low maintenance, cheap laboratory breeding, high evolutionary parallels and physiological relatedness to humans, and easy availability of many inbred strains make mouse models most commonly employed for research of human biology and illness most relevant.
Moreover, mice have a somewhat limited lifespan and reproductive cycle. This feature allows scientists to investigate several generations of mice in a rather limited amount of time. Thus, various benefits provided by mice animal model is set to drive the segment trends.
Learn more about the key segments shaping this market
Development of new medicines and research on human diseases benefit much from animal models. Various technologies—including CRISpen, microinjection, embryonic stem cell injection, and nuclear transfer—can be used to build these models. Powerful new technology called CRISpen makes animal gene editing simpler than it has ever been possible. A great variety of fresh animal models more realistic and user-friendly than conventional models have resulted from this technologies. Animal model study has been transformed by CRISpen. It has made it feasible to produce animals with more exact genetic changes, which has advanced knowledge of human diseases and helped shape new treatments. CRISpen operates like followsWith CRISpen, scientists create a tiny cut in the DNA at the intended site. The cell then fixes the cut with its own DNA repair system. The CRISpen system can be built by scientists to alter the sequence of genes or to insert or remove particular ones. Though it is still a quite recent technology, CRISpen has already had a significant influence on animal model studies. It is probably still very important for the evolution of fresh treatments for human ailments.
Research and development, manufacturing and quality control, academia, preclinical applications and other uses define the animal model market based on application. With majority market share in 2022, the research and development category is predicted to see considerable expansion to USD 22.1 billion by 2032. The segment share is expected to be driven by the growing number of research and development initiatives as well as by the rising investments to create new treatments. Some of the first advancements about the disease and to identify possible pharmacological targets are based on animal models.
Every drug candidate's gastrointestinal absorption, distribution, metabolism, and drug excretion (ADME) properties are further evaluated by pharmacokinetic and pharmacodynamic studies. These ADME studies that help to filter these medication candidates to proceed to the next stage in safety and effectiveness investigations make considerable use of animal models.
Based on use, the animal model market is segmented into human and veterinary. The human segment accounted for largest revenue share in 2022 and is anticipated to grow at significant 7.0% growth rate during the analysis period. This significant segmental revenue is majorly attributed to the increasing prevalence of chronic disorders such as cancer in humans and increasing demand for personalized medicine. According to the World Health Organization (WHO), in 2020, cancer is amongst the critical conditions inflicting substantial disease burden, accounting for approximately 10 million deaths.
Comparably, according to Cancer Statistics, the United States alone accounted for almost 1.8 million new cancer cases diagnosed in 2020. Consequently, the increasing frequency of such chronic human diseases is expected to stimulate the need for new treatments and efficient medications. This need in turn is predicted to drive the use of animal models in medication research and development, therefore improving the segment outlook.
Learn more about the key segments shaping this market
Businesses, charities, colleges, and contract research organisations (CROs) among other users find fit in the animal testing industry. Businesses used animal testing most famously in 2022. This is so because biotechnology and pharmaceutical businesses mostly depend on animal models for their operations and invest much in research and development. For instance, a Johnson & Johnson analysis revealed that top 11 businesses spent USD 77.6 billion on R&D expenses, up by 5%. From the early phases of research to human trials, animal models are absolutely essential for guiding decisions on whether or not to create novel therapies. The usage of animal models is projected to keep increasing as governments and businesses spend more in healthcare and people want better treatments.
Looking for region specific data?
The animal model market in North America is poised to soar at an impressive 7.1% growth rate over the coming years. What's driving this growth? A surge in investments and a remarkable increase in clinical trials conducted right here in our backyard. The market is bustling with big names in the mice model industry, who are giving it a much-needed boost. And it's not just them—biomedical research is booming in the U.S., and both CROs (contract research organizations) and pharmaceutical giants are ramping up their preclinical activities in the region. As a result, the number of clinical trials is skyrocketing, and investors are pouring money into these studies. This growing demand for animal models is fueling the market's expansion, promising to make it a major player in the global animal model industry.
Animal Model Market Share
Major market players operating in the animal model market include
- Charles River Laboratories, Inc.
- Envigo
- GenOway
- Harbor BioMed
- Trans Genic Inc.
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Animal Model Industry News
- In March 2022, Charles River Laboratories signed an agreement with Hera Biolabs to breed, distribute, market, and sell Hera BioLabs' SRG rat to the global preclinical research community. This strategic move helped the company to diversify their product portfolio thereby increasing their geographical presence.
- In October 2021, JACKSON LABORATORY announced the acquisition of Charles River Laboratories, Japan. The acquisition is intended to extend the firm’s animal model business, including advanced immunodeficient models and humanized mice along with expanding the firm’s presence in Japan. The company's animal model solutions will benefit from this launch that will help them boost the business development.
The animal model market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Animal Type
- Mice
- Rats
- Fish
- Birds
- Cattles
- Pigs
- Amphibians
- Guinea Pigs
- Dogs
- Cats
- Rabbits
- Monkeys
- Sheep
- Hamsters
- Other animal types
By Technology
- CRISPR
- Microinjection
- Embryonic Stem Cell Injection
- Nuclear Transfer
- Other technologies
By Application
- Research & Development
- Infectious Disease
- Immunological Diseases
- Cancer
- Cardiovascular Diseases
- Diabetes
- Genetic Diseases
- Neurological Diseases
- Obesity
- NAFLD/NASH
- Renal Disease
- Diabetic Eye Disease
- Fibrosis
- Microbiome
- Other Research & Development Applications
- Production and Quality Control
- Academics
- Preclinical Applications
- Infectious Disease
- Immunological Diseases
- Cancer
- Cardiovascular Diseases
- Diabetes
- Genetic Diseases
- Neurological Diseases
- Obesity
- NAFLD/NASH
- Renal Disease
- Diabetic Eye Disease
- Fibrosis
- Microbiome
- Other Preclinical Applications
- Other Applications
By Use
- Human
- Veterinary
By End-use
- Companies
- Pharmaceutical
- Biotechnology
- Cosmetics
- Other Companies
- Organizations
- Government
- Non-government
- Academic and Research Institutes
- Contract Research Organizations (CRO)
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Switzerland
- Netherlands
- Czech Republic
- Poland
- Belgium
- Finland
- Hungary
- Denmark
- Ireland
- Sweden
- Rest of Europe
- Asia Pacific
- China
- Japan
- Australia
- South Korea
- New Zealand
- Taiwan
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Israel
- Rest of MEA
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy